|
PolyMedix focuses on developing novel high-value therapeutic drug products for serious, life-threatening acute disorders. We attack these challenges with biomimetics - novel small molecule compounds and polymers which mimic the activity of proteins. These compounds are designed with a proprietary computational technology platform which focuses on a specific field of biology with many potential product opportunities: membrane:protein and protein:protein interactions.
PolyMedix focuses on serious, life threatening, acute disorders which are also significant market opportunities. Using our proprietary computational drug design technology, we have created novel antibiotic compounds and heptagonists. Our lead candidates in each of these programs, i.v. antibiotic candidate PMX-30063 and the anticoagulant antagonist product candidate PMX-60056, are currently in advanced preclinical development. We plan to file Investigational New Drug applications with the U.S. Food and Drug Administration for each during the first quarter of 2008.
PolyMedix is a publicly traded company (OTC BB:PYMX).
May 9, 2008
PolyMedix Receives Regulatory Clearance to Initiate Phase I Clinical Study
of Novel Systemic Antibiotic Compound
PMX-30063 The First Defensin Mimetic Systemic Antibiotic Drug
Cleared For Human Clinical Trials
PolyMedix, Inc. (OTC BB: PYMX), an
emerging biotechnology company developing acute care products for infectious diseases and
acute cardiovascular disorders based on biomimetics, has received a notice of no objection from
Health Canada for the Company’s Clinical Trial Application (“CTA”) for its defensin mimetic
antibiotic compound, PMX-30063. This notice of no objection allows for the initiation of human
clinical studies in Canada. PMX-30063 is the first defensin mimetic antibiotic compound cleared
to enter human clinical trials for systemic use, representing an entirely new class of antibiotic
drugs. »read more
|
|
|
April 11, 2008
DR. WILLIAM DEGRADO HONORED WITH
THE RALPH F. HIRSCHMANN AWARD IN PEPTIDE CHEMISTRY
Dr. William DeGrado, the scientific founder of PolyMedix, Inc. (OTC BB: PYMX), was named the 2008 recipient of the prestigious Ralph F. Hirschmann Award in Peptide Chemistry. The award recognizes a person who has made outstanding contributions in the chemistry, biochemistry, or biophysics of peptides. »read more
|
|
